Literature DB >> 11302875

Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjögren's syndrome.

M M Zandbelt1, F H van den Hoogen, P C de Wilde, P J van den Berg, H G Schneider, L B van de Putte.   

Abstract

Sjögren's syndrome (SS) is a chronic autoimmune disease characterised by specific lesions in exocrine glands, so sublabial minor salivary gland biopsy (SLGB) plays an important part in its diagnosis. The extent and composition of the lymphocytic infiltrate in SLGB specimens can be considered as target organ specific parameters. They are quantified after histological and immunohistological examination by a focus score (describing the extent of the infiltrate) and IgA% score (describing the composition of the infiltrate), respectively. However, little is known about the factors that contribute to the extent and composition of the infiltrate and whether these features are reversible as repeated SLGBs are rarely performed. A patient with SS is described who underwent SLGBs before and after treatment with high dose corticosteroids. After treatment there was not only clinical improvement, but also improvement in the histological and immunohistological parameters. Although these findings need to be confirmed in further studies, this suggests that histopathological changes may be reversible in SS. Furthermore, it shows that the potential effects of corticosteroid use should be taken into account when interpreting SLGB specimens. When clinical changes do parallel histological changes, repeated SLGBs might offer a marker for disease activity in patients with SS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11302875      PMCID: PMC1753654          DOI: 10.1136/ard.60.5.511

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  Progression of salivary gland dysfunction in patients with Sjogren's syndrome.

Authors:  J Pijpe; W W I Kalk; H Bootsma; F K L Spijkervet; C G M Kallenberg; A Vissink
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

Review 2.  Conventional therapy of Sjogren's syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

3.  Diagnostic utility of Acoustic Radiation Force Impulse (ARFI) imaging in primary Sjoegren`s syndrome.

Authors:  Andreas Knopf; Benedikt Hofauer; Klaus Thürmel; Reinhard Meier; Konrad Stock; Murat Bas; Naglaa Manour
Journal:  Eur Radiol       Date:  2015-04-11       Impact factor: 5.315

4.  [Labial salivary gland biopsy in Sjögren's syndrome].

Authors:  A Dankof; L Morawietz; E Feist
Journal:  Pathologe       Date:  2006-11       Impact factor: 1.011

Review 5.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

6.  IL-17A and IL-17F polymorphisms in rheumatoid arthritis and Sjögren's syndrome.

Authors:  Camila Nunes Carvalho; Rodrigo Feliciano do Carmo; Angela Luzia Pinto Duarte; Alessandra Albuquerque Tavares Carvalho; Jair Carneiro Leão; Luiz Alcino Gueiros
Journal:  Clin Oral Investig       Date:  2015-08-02       Impact factor: 3.573

7.  Clinical and laboratorial profile and histological features on minor salivary glands from patients under investigation for Sjögren's syndrome.

Authors:  Débora-Lima Pereira; Verônica-Silva Vilela; Teresa-Cristina-Ribeiro-Bartholomeu Dos Santos; Fábio-Ramôa Pires
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-05-01

Review 8.  T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives.

Authors:  Alessia Alunno; Francesco Carubbi; Onelia Bistoni; Sara Caterbi; Elena Bartoloni; Giulia Mirabelli; Francesca Cannarile; Paola Cipriani; Roberto Giacomelli; Roberto Gerli
Journal:  Mediators Inflamm       Date:  2015-04-28       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.